Avastin filed for first-line breast cancer use in Japan
This article was originally published in Scrip
Executive Summary
Roche's Japanese subsidiary, Chugai, has filed for the approval of the anti-VEGF monoclonal antibody drug Avastin (bevacizumab) for the first-line treatment of advanced or recurrent breast cancer.